Versatile CAR T-cells for cancer immunotherapy

Fuliang Chu; Jingjing Cao; Sattva S. Neelalpu

doi:10.5114/wo.2018.73892

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Contemporary Oncology

1/2018

Send email

Copy url:

abstract:

Review paper

Versatile CAR T-cells for cancer immunotherapy

Fuliang Chu

,

Jingjing Cao

,

Sattva S. Neelalpu

Contemp Oncol (Pozn) 2018; 22 (1A): 73–80

DOI: https://doi.org/10.5114/wo.2018.73892

Online publish date: 2018/03/08

View full text Get citation

PlumX metrics:

Chimeric antigen receptor (CAR) T-cell therapy has been clinically proven to efficiently combat haematological malignancies. However, continuous efforts are required to increase the specificity of CAR T-cells against tumour versus normal tissues, and are essential to improve their antitumour activity in solid tumours. This review summarises the structure of major CAR designs, and strategies to overcome immunosuppressive tumour microenvironment, and reduce toxicities. Along with reviewing currently available techniques that allow the elimination of CAR T-cells after they fulfil their desired functions, using suicide genes, drug elimination strategies are also introduced. A better understanding of the strengths and pitfalls of CAR T-cell therapy will provide fundamental knowledge for the improvement of engineered T-cell therapy in the near future.

keywords:

Versatile CAR T-cells for cancer immunotherapy

Fuliang Chu , Jingjing Cao , Sattva S. Neelalpu

chimeric antigen receptor, CAR T-cell therapy, haematological and solid tumors

Fuliang Chu

,

Jingjing Cao

,

Sattva S. Neelalpu